How it works?
Senza categoria

Expanding the Spectrum of Lesions with COL1A1:: PDGFB Fusion: three unusual myofibroblastic lesions


et al. Gerardo Cazzato

USCAP

DESCRIPTION

USCAP 2025 Scientific PosterDownload

Back



RELATED ARTICLES

Reliability of programmed death ligand 1 (PD-L1) tumor proportion scor...

Costantino Ricci, Elisa Capizzi and others...


Therapeutic Advances in Medical Oncology
Microfix

Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assessment is mandatory for the single agent pembrolizumab treatment of patients...



Anti-hepatocellular carcinoma treatment in liver models...

Callegari...


Molecular Therapy: Nucleic Acid
Micromount

Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palboci...



Diapath Lab Talks | Privacy Policy